Phreesia, Inc. (NYSE:PHR) SVP David Linetsky Sells 720 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 720 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $29.50, for a total value of $21,240.00. Following the completion of the sale, the senior vice president now directly owns 230,051 shares of the company’s stock, valued at approximately $6,786,504.50. The trade was a 0.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David Linetsky also recently made the following trade(s):

• On Wednesday, January 29th, David Linetsky sold 500 shares of Phreesia stock. The shares were sold at an average price of $29.68, for a total transaction of $14,840.00.
• On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $321,103.80.
• On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $25.38, for a total transaction of $609.12.
• On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The stock was sold at an average price of $24.88, for a total transaction of $870.80.
• On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The stock was sold at an average price of $24.85, for a total value of $294,547.05.

Phreesia Price Performance

Shares of PHR opened at $28.98 on Friday. The stock’s 50-day moving average price is $25.82 and its 200 day moving average price is $23.46. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.90.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia’s revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.58) earnings per share. On average, analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Phreesia

Institutional investors have recently made changes to their positions in the business. Versor Investments LP bought a new position in Phreesia during the third quarter worth about $694,000. Zacks Investment Management acquired a new position in shares of Phreesia in the 3rd quarter worth approximately $631,000. State Street Corp lifted its position in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after buying an additional 88,517 shares during the period. Wesbanco Bank Inc. boosted its stake in Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after buying an additional 20,000 shares in the last quarter. Finally, Barclays PLC grew its position in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after acquiring an additional 43,225 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PHR. KeyCorp upped their target price on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Citigroup upped their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Robert W. Baird dropped their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Finally, Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.